• Users Online: 49
  • Print this page
  • Email this page
MINI REVIEW
Year : 2022  |  Volume : 2  |  Issue : 1  |  Page : 36-39

Detection of antinuclear antibodies in oncology from slide to multiplexing: An overview


1 Department of Laboratory Medicine, Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India
2 Oncquest, Dr G Path Labs, New Delhi, India
3 Dr. Anita's Laboratories, Karnal, Haryana, India
4 Department of Clinical Pathology, Ahhalia Hospital Musaffah Industrial, Abu Dhabi, UAE
5 Centre for Academic Research, HCG Cancer Center, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Amrit Kaur Kaler
Consultant Molecular Pathologist, Department of Laboratory Medicine, Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpo.jpo_11_22

Rights and Permissions

Antinuclear antibodies (ANA) are autoantibodies considered as the immune biomarkers of systemic autoimmune diseases. ANAs are directed against antigens of the cell nucleus and are named after their biochemical characteristics (deoxyribonucleic acid [DNA], histones, ribonucleoprotiens), the disease is associated with the corresponding autoantibody, e.g., Sjögren syndrome antigen A [SS-A] and Systemic Sclerosis (SS-B); progressive systemic sclerosis, polymyositis, or occasionally after the patient in whom the corresponding antibody was first detected (Sm, Ro, La). Positive ANA can also be used as an aid to early diagnosis of solid tumors and prognosis in hematological malignancies such as non-Hodgkin's lymphoma patients. Positive ANA has been found in the sera from patients with head and neck, lung, breast cancers by multiple studies. Most commonly patients with chronic lymphocytic leukemia (CLL) frequently present with autoimmune disorders (AIDs) which include autoimmune hemolytic anemia (AIHA), immune thrombocytopenia, pure red cell aplasia and autoimmune granulocytopenia, and nonhematological AIDs such as paraneoplastic pemphigus, neuropathies, SS, rheumatoid arthritis, and systemic lupus erythematosus. The presence of AIHA was previously demonstrated to be a poor prognostic indicator and also proved the negative survival impact of positive direct antiglobulin test on CLL patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed328    
    Printed24    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal